0000899243-21-029582.txt : 20210722 0000899243-21-029582.hdr.sgml : 20210722 20210722205855 ACCESSION NUMBER: 0000899243-21-029582 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210722 FILED AS OF DATE: 20210722 DATE AS OF CHANGE: 20210722 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: O'Byrne Jason CENTRAL INDEX KEY: 0001871145 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40631 FILM NUMBER: 211108861 MAIL ADDRESS: STREET 1: CARIBOU BIOCIENCES, INC. STREET 2: 2929 7TH STREET, SUITE 105 CITY: BERKELEY STATE: CA ZIP: 94710 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Caribou Biosciences, Inc. CENTRAL INDEX KEY: 0001619856 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 453728228 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2929 7TH STREET, SUITE 105 CITY: BERKELEY STATE: CA ZIP: 94710 BUSINESS PHONE: 510-982-6030 MAIL ADDRESS: STREET 1: 2929 7TH STREET, SUITE 105 CITY: BERKELEY STATE: CA ZIP: 94710 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-07-22 0 0001619856 Caribou Biosciences, Inc. CRBU 0001871145 O'Byrne Jason C/O CARIBOU BIOSCIENCES, INC. 2929 7TH STREET, SUITE 105 BERKELEY CA 94710 0 1 0 0 See Remarks Stock Option (Right to Buy) 4.11 2031-03-29 Common Stock 437201 D Stock Option (Right to Buy) 5.27 2031-06-28 Common Stock 48966 D 1/4th of the shares subject to this option will vest on February 28, 2022 and an additional 1/48th of the aggregate number of shares subject to the option will vest on the corresponding day of each month thereafter (or if there is no such corresponding day, on the last day of such month), subject to the reporting person's continued service to the Issuer thorough the applicable vesting date. 1/4th of the shares subject to this option will vest on June 29, 2022 and an additional 1/48th of the aggregate number of shares subject to the option will vest on the corresponding day of each month thereafter (or if there is no such corresponding day, on the last day of such month), subject to the reporting person's continued service to the Issuer thorough the applicable vesting date. Chief Financial Officer Exhibit 24 - Power of Attorney. /s/ Jason V. O'Byrne 2021-07-22 EX-24 2 attachment1.htm EX-24 DOCUMENT

                                                                      Exhibit 24

                                 POWER OF ATTORNEY

    With respect to holdings of and transactions in securities issued by Caribou
Biosciences, Inc. (the "Company"), the undersigned hereby constitutes and
appoints the individuals named on Schedule A attached hereto and as may be
amended from time to time, or any of them signing singly, with full power of
substitution and resubstitution, to act as the undersigned's true and lawful
attorney-in-fact to:

    1.  execute for and on behalf of the undersigned, Schedules 13D and 13G in
accordance with Section 13 of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), and the rules thereunder, and Forms 3, 4, and 5 in
accordance with Section 16 of the Exchange Act and the rules thereunder;

    2.  do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Schedule
13D or 13G or Form 3, 4, or 5, complete and execute any amendment or amendments
thereto, and timely file such schedule or form with the SEC and any stock
exchange or similar authority; and

    3.  take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

    The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution and
resubstitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted.

    The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 13 and Section 16 of the Exchange Act.

    This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Schedule 13D and 13G and Forms 3,
4,and 5 with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the undersigned in a
signed writing delivered to the foregoing attorneys-in-fact.

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 22nd day of July, 2021.


                                          /s/ Jason V. O'Byrne
                                        ----------------------------------------
                                        Jason V. O'Byrne


                                     Schedule A

    Individuals Appointed as Attorney-in-Fact with Full Power of Substitution
and Resubstitution

1.  Rachel E. Haurwitz
2.  Barbara E. McClung
3.  Ryan Fischesser